EA202090916A1 - Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией - Google Patents

Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией

Info

Publication number
EA202090916A1
EA202090916A1 EA202090916A EA202090916A EA202090916A1 EA 202090916 A1 EA202090916 A1 EA 202090916A1 EA 202090916 A EA202090916 A EA 202090916A EA 202090916 A EA202090916 A EA 202090916A EA 202090916 A1 EA202090916 A1 EA 202090916A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
acetate
prostate cancer
androgen
abirateron
Prior art date
Application number
EA202090916A
Other languages
English (en)
Russian (ru)
Inventor
Нампхуонг Тран
Original Assignee
Янссен Онколоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Онколоджи, Инк. filed Critical Янссен Онколоджи, Инк.
Publication of EA202090916A1 publication Critical patent/EA202090916A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Engineering & Computer Science (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202090916A 2017-10-11 2018-02-08 Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией EA202090916A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11
PCT/US2018/017438 WO2019074536A1 (en) 2017-10-11 2018-02-08 METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY

Publications (1)

Publication Number Publication Date
EA202090916A1 true EA202090916A1 (ru) 2020-12-11

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090916A EA202090916A1 (ru) 2017-10-11 2018-02-08 Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией

Country Status (16)

Country Link
US (2) US20190105332A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694604A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020536903A (cg-RX-API-DMAC7.html)
KR (1) KR20200068689A (cg-RX-API-DMAC7.html)
CN (1) CN111542373A (cg-RX-API-DMAC7.html)
AU (1) AU2018347804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007090A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077678A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090916A1 (cg-RX-API-DMAC7.html)
IL (1) IL273826A (cg-RX-API-DMAC7.html)
JO (1) JOP20200072A1 (cg-RX-API-DMAC7.html)
MA (1) MA50341A (cg-RX-API-DMAC7.html)
MX (1) MX2020003830A (cg-RX-API-DMAC7.html)
PH (1) PH12020550151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124865C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019074536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
JP2023524794A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Also Published As

Publication number Publication date
WO2019074536A1 (en) 2019-04-18
UA124865C2 (uk) 2021-12-01
PH12020550151A1 (en) 2021-02-08
JOP20200072A1 (ar) 2020-04-29
US20200069704A1 (en) 2020-03-05
AU2018347804A1 (en) 2020-04-16
IL273826A (en) 2020-05-31
CA3077678A1 (en) 2019-04-18
BR112020007090A2 (pt) 2020-09-24
MX2020003830A (es) 2020-11-06
KR20200068689A (ko) 2020-06-15
CN111542373A (zh) 2020-08-14
MA50341A (fr) 2020-08-19
EP3694604A1 (en) 2020-08-19
US20190105332A1 (en) 2019-04-11
JP2020536903A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
ZA202501583B (en) Compounds and methods for the targeted degradation of androgen receptor
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
JOP20230159A1 (ar) تركيبة علاجية لسرطان البروستاتا
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MA39906A (fr) Polythérapies pour le traitement du cancer
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
PH12020550151A1 (en) Methods of treating prostate cancer
GB2568000A (en) Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
MX2020001727A (es) Terapia de combinacion.
MX2016009515A (es) Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
TW201613587A (en) Medical treatments based on anamorelin
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
JOP20220288A1 (ar) علاج سرطان البروستات بتوليفة من أبيراتيرون أسيتات ونيراباريب
MY197942A (en) Adjuvant therapy for use in prostate cancer treatment
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EA201891005A1 (ru) Комбинированная терапия рака
EA202190291A1 (ru) Комбинированная терапия для лечения рака
EA201990411A1 (ru) Способы лечения рака предстательной железы
EA201890956A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
UA97456U (en) METHOD FOR THE TREATMENT OF PATIENTS WITH CERVICAL CANCER of II-III stage
EA201691907A1 (ru) Комбинированная терапия кураксинами